Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel; April W. Armstrong; Richard B. Warren; Kim Papp; Diamant Thaçi; Alan Menter; Jennifer Clay Cather; Matthias Augustin; Lauren Hippeli; Carolin Daamen; Christopher Em Griffiths

doi:10.25251/skin.6.supp.47

Article2023

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Clay Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Em Griffiths

Article2023

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher Em Griffiths

Article2018

AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial

Christopher Em Griffiths, Kim Papp, Alexa B. Kimball, B. Randazzo, Yasmine Wasfi, S. Li, Yaung‐Kaung Shen, Andrew Blauvelt

Article2015

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial

Robert Bissonnette, Lars Iversen, Howard Sofen, Christopher Em Griffiths, Peter Foley, Ricardo Romiti, Mary Bachinsky, Scott T. Rottinghaus, Hsiewe Ying Tan, James Proulx, H. Valdez, Pankaj Gupta, Lotus Mallbris, Robert Wołk

Article2018

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Christopher Em Griffiths, Kim Papp, Alexa B. Kimball, B. Randazzo, Michael Song, Shu Li, Yaung‐Kaung Shen, Andrew Blauvelt

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Abstract

Discussion(0)

Related publications

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.